Overview - As demand for GLP-1 drugs continues to skyrocket, federal and state agencies are turning their attention to the GLP-1 ...

Scholar Rock Holding Corporation (NASDAQ:SRRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Scholar Rock ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment.ARD-201 was also associated with attenuated weight regain ...

Recent research suggests a possible increased risk of serious eye conditions, such as non-arteritic anterior ischaemic optic ...

Two studies were conducted to verify concerns about diabetic retinopathy that were raised during initial trials of ...

New studies indicate that weight-loss drugs may lead to serious eye diseases and vision loss in some individuals, prompting ...

Study links weight-loss drugs to serious eye conditions and vision loss - Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye co ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

The Government has announced a pilot to test new ways to support patients living with obesity, in a bid to ease pressures on ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...